Separately, Zacks Investment Research upgraded shares of Q BioMed from a “hold” rating to a “buy” rating and set a $2.75 price objective on the stock in a research note on Saturday, January 18th.
QBIO stock opened at $2.51 on Thursday. The firm has a 50 day simple moving average of $2.02 and a 200-day simple moving average of $1.20. The company has a market capitalization of $51.40 million, a P/E ratio of -3.69 and a beta of 5.26. Q BioMed has a twelve month low of $0.34 and a twelve month high of $2.55.
About Q BioMed
Q BioMed Inc, a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89, a radiopharmaceutical therapeutic for the treatment of bone cancer pain therapies. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; BM-001 for the treatment of rare pediatric nonverbal autism spectrum disorder; and Uttroside-B for liver cancer.
Featured Story: What is included in the gross domestic product?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Q BioMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Q BioMed and related companies with MarketBeat.com's FREE daily email newsletter.